Sialyl-Lewis X (SLe^x) Antigen Inhibitor Development Service at CD BioGlyco

SLe^x is a salivary lase-acidified polytetrasaccharide that is an endogenous antigen. It occurs highly expressed in the cells of many epithelial tumors. In turn, SLe^x antigen inhibitors interfere with the proliferation and differentiation of certain tumor cells. Therefore, research on the development of SLe^x antigen inhibitors is of great importance in glycobiology. At CD BioGlyco, we offer SLe^x antigen inhibitor development services.

• SLe^x antibody development service

SLe^x antibodies have the specificity to recognize SLe^x antigens and can bind as well as clear SLe^x antigens. We offer a variety of tools to develop SLe^x antibodies:

• Hybridoma technology: We use animal models to produce monoclonal antibodies by fusing sensitized B cells, which secrete specific antibodies, and myeloma cells, which can multiply indefinitely, into hybridoma cells through a process of animal immunization, cell fusion, hybridoma, and subclonal screening. This technique produces highly homogeneous SLe^x antibodies directed only against specific SLe^x antigens.
• Antibody library screening technology: Utilizing the SLe^x antibody library, we perform incubation experiments after gradient dilution of SLe^x antigen to observe the expression effect of SLe^x antigen. We perform a total of three rounds of screening, and each round of elution is followed by titer measurement. Finally, we compare with the control group to screen out reliable antibodies to the SLe^x antigen.

• Small molecule-based SLe^x antigen inhibitor development service
  We provide high-throughput screening combined with fluorescent labeling of biological small molecules that interfere with the synthesis of SLe^x antigens. Then, we derivatize and modify the screened small molecules and evaluate their effectiveness in inhibiting SLe^x antigens. Finally, their inhibitory activities are compared to obtain small molecule inhibitors of SLe^x antigen.

Fig.1 SLe^x antigen inhibitor development service. (CD BioGlyco)

Publication

Journal: Journal of Chemical Information and Modeling

IF: 5.6

Published: 2021

Results: Selectins interact with cell surface glycans to promote initial leukocyte bundling and rolling, and these interactions are the targets for the design of inhibitors. The heterodimeric endogenous tetrasaccharides, SLe^x and SLe^a are the minimal glycan structures required for selectin binding. Understanding their subtle structural differences is beneficial for the rational design of the corresponding inhibitors. Crystal structures based on modeling of E-selectin-SLe^x suggest that the N-acetyl group of GlcNAc in SLe^x can form a spatial site barrier in the E-selectin-SLe^x complex, but the hydroxy methylene group of GlcNAc in sLe permits stronger binding interactions at the same position. Subsequently designed inhibitors with synthetic accessible junction molecules that did not displace the exocyclic portion of GlcNAc showed dynamic and energetic binding characteristics comparable to those of SLe^a. The inhibitors were also designed to be able to bind to GlcNAc in the SLe^a complex.

Applications

• The development of SLe^x antigen inhibitors can be used to develop antiviral and anti-cancer agents.
• The development of SLe^x antigen inhibitors drives innovation in the field of carbohydrate-based vaccines.
• The development of SLe^x antigen inhibitors can be used in therapeutic studies of tumors.

Advantages

• Our antigen research and development team provides our clients with custom production solutions according to their requirements.
• Our service team is responsive and proactive to ensure a positive client experience and satisfaction.
• We have high-quality, efficient, and stable antigen inhibitor development technology.

CD BioGlyco has extensive experience in glycobiology research. We have developed a dependable Glycosylation Inhibitor Development Service to assist our clients in solving their glycosylation challenges. If you are interested in our services, please contact us for more details without any hesitation.